Shopping Cart
- Remove All
Your shopping cart is currently empty
Emactuzumab
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
Catalog No. T76776Cas No. 1448221-67-7
Select Batch
Concentration:3.74 mg/mL
Purity:SDS-PAGE:98.3%;SEC-HPLC:97.3%
Contact us for more batch information
Resource Download
Emactuzumab
Catalog No. T76776Cas No. 1448221-67-7
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $328 | In Stock | |
| 5 mg | $747 | In Stock | |
| 10 mg | $1,160 | In Stock | |
| 25 mg | $1,720 | In Stock | |
| 50 mg | $2,290 | In Stock | |
| 100 mg | $3,120 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Emactuzumab"
Gilteritinib
Cited
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
- $34
Size
QTY
CitedPexidartinib Cited
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.
- $40
Size
QTY
CitedPLX5622 Cited
T71001303420-67-8
PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor.
- $97
Size
QTY
CitedSotuletinib Cited
T6119953769-46-5
Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase homologs.
- $31
Size
QTY
CitedPazopanib Hydrochloride
T6930635702-64-6
Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
- $48
Size
QTY
Cabozantinib S-malate
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
- $40
Size
QTY
Masitinib
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
UNC2025
T70071429881-91-3
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
- $33
Size
QTY
Bemcentinib Cited
T62691037624-75-1
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
- $34
Size
QTY
CitedSitravatinib Cited
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT). |
| In vitro | RG7155 (30 μg/mL; 6 days) induces cell death of in vitro-differentiated human M2-like macrophages.[2] Inducing cell death, RG7155 (0-10 μg/mL; 7 days) inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM.[2] Emactuzumab, with a high affinity binding to human and cynomolgus CSF-1R (Kd = 0.2 nM), effectively prevents CSF-1R dimerization.[2] |
| In vivo | Emactuzumab (0.1、1、10、30 and 100 mg/kg; i.v.; once; male cynomolgus monkey) increased CSF-1 concentration in serum.[2] RG7155 (0, 30, and 100 mg/kg; i.v.; once weekly; for 2 weeks; male and female cynomolgus) Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.[2] |
| Alias | RO 5509554, RG 7155 |
| Cas No. | 1448221-67-7 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Emactuzumab | purchase Emactuzumab | Emactuzumab cost | order Emactuzumab | Emactuzumab chemical structure | Emactuzumab in vivo | Emactuzumab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.